Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Double digit FY growth for key brands Cosentyx USD 4.7 bn +17% Entresto zolgensma® KISQALIⓇ 1 GROWTH YCE AZ K KL Kesimpta LEQVIO® USD 3.5 bn USD 1.4 bn USD 0.9 bn USD 0.4 bn nm +40% +46% +36% nm nm Est. CAGR (2020-26) Low double digit Peak sales USD >7bn US LOE 2029+ Est. CAGR (2020-26) Double digit until LoE Peak sales USD >5bn US LOE 2025-2036 Est. CAGR (2020-26) Low to mid teens Peak sales multi-bn¹ US LOE 2031+ Est. CAGR (2020-26) Low 30s² Peak sales multi-bn US LOE 2031+ Est. CAGR (2020-26) nm Peak sales multi-bn US LOE 2031+ Est. CAGR (2020-26) nm Peak sales multi-bn US LOE 2036+ nm - Not meaningful. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including Zolgensma IT. 2. Including Kisqali adjuvant. 11 Investor Relations | Q4 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation